N/A N=36 Palatability of Experimental Cigarettes - Study 2
Smoking
Primary: Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 — -16.2; -7.6; 1.3 nmols/ml
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=31 Impact of Exclusive Use of Low Nicotine Cigarettes on Compensatory Smoking
Smoking
Primary: Breath Sample (Expired Carbon Monoxide) — 18.77; 31.07; 25.38; 30.49 parts per million — p=0.92
N/A N=136 Reduced Nicotine Content Cigarettes and Tobacco Switching Behaviors
Tobacco Addiction · Dual Tobacco Use
Primary: Number of Days Using Alternative Products — 14; 26; 20 Number of days
N/A N=1,132 Correcting Public Misperceptions About Very Low Nicotine Content Cigarettes
Tobacco Use, Cigarette Use
Primary: Very Low Nicotine Content (VLNC) Misperception — 3.12; 3.04; 3.04; 3.36 score on a scale
N/A N=37 Cigarette Smoking Decision Study
Tobacco Smoking
Primary: Demand Intensity as Assessed by a Behavioral Economic Demand Curve — 4.709677419; 2.580645161 puff bouts
N/A N=139 Cigarette Smoking Among Young Adults
Cigarette Smoking · Smoking Behaviors
Primary: Puff Topography — 1108; 1045.2; 1084.6 mL
Phase 2 N=130 Health Effects of SLT, Cigarette Smoking, and New Tobacco Products
Nicotine Dependence
Primary: Toxicant Exposure by Products — 835.3; 782.1; 726.8; 0.157 ng/ml — p=0.002
N/A N=31 Cigarette Smoking in Smokers With and Without Schizophrenia
Tobacco Dependence · Schizophrenia
Primary: End-of-session Carbon Monoxide — 62.7; 43.0 parts per million (ppm)
N/A N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Women of Reproductive Age
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
N/A N=104 Evaluation of Oral Tobacco as a Harm Reduction Method for Smokers
Tobacco Use Disorder
Primary: Product Preference — 27; 23; 24; 24 participants
N/A N=1,257 Effects of FDA Authorized Smokeless Tobacco Claims Among US Adults Who Smoke Cigarettes
Tobacco Product Beliefs and Use
Primary: General Relative Harm Perception — 3.04; 2.76; 2.84; 3.19 score on a scale
N/A N=30 Sugars in Cigarettes
Tobacco Use
Primary: Impact of Cigarette Sugar Content on Product Satisfaction. — 4.09; 3.89; 3.92; 4.39 units on a scale
N/A N=80 Low Nicotine Cigarettes Plus Electronic Cigarettes
Tobacco Dependence
Primary: Urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) — 505.6; 459.1; 373.3; 180.5 pg/mg creatinine — p=0.017
N/A N=40 Acute Effects of Cigarette Packaging and Charcoal Filtration on Perceptions, Use Behaviors, and Harm Exposure
Smoking Behaviors
Primary: Number of Puffs Taken (Video-scored Smoking Behavior Outcome 1) — 15.8; 16.7; 19.1; 19.6 puffs
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders
Tobacco Use Disorder
Primary: Cigarettes Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 4 N=179 Smoking Tobacco and Drinking Study
Smoking · Heavy Episodic Drinking
Primary: Number of Participants With Reported 7-day Point Prevalence Abstinence at 3 Months — 3; 4 Participants
N/A N=64 Cigarette and E-cigarette Nicotine Content in an Electronic Tobacco Marketplace (ETM)
Tobacco Use
Primary: Number of Cigarettes Purchased — 154.7; 119.2 average number of cigarettes
N/A N=50 Project 2 Cigarette and E-cigarette Nicotine Content and E-liquid Flavors
Smoking
Primary: Total Cigarettes Smoked Per Day — 21.6; 7.7; 18.4; 12.5 number of cigarettes
N/A N=789 Enhancing Source Credibility in Tobacco Regulatory Communications
Cigarette Smoking Behavior
Primary: Quit Intentions — 2.73; 2.67; 2.58 score on a scale
Phase 2 N=49 Impact of Nicotine Reduction on Adolescent Cigarette Use, Alternative Tobacco Use, and Harm From Tobacco
Nicotine Dependence, Cigarettes, Uncomplicated
Primary: Average Cigarettes Smoked Per Day — 4.3; 8.0 average cigarettes per day — p=.111
Phase 2 N=326 Low Nicotine Content Cigarettes in Vulnerable Populations: Opioid Use Disorder
Tobacco Use Disorder
Primary: Number of Cigarettes Smoked Per Day — 22.54; 14.32; 11.76; 7.63 cigarettes per day
Phase 3 N=81 Nicotine Lozenge or Tobacco-Free Snuff for Smokeless Tobacco Reduction
Tobacco Dependence
Primary: Tobacco Abstinence at 12 Weeks — 8; 5 participants
N/A N=67 Clinical Trial Tobacco Marijuana
Cannabis Use Disorder · Tobacco Use Disorder
Primary: Tobacco Quit Attempts — 13; 17 Participants — p== 0.33
N/A N=10 IQOS (Non-Cigarette Tobacco Product) Pilot Study
Smoking · Tobacco Use
Primary: Number of Participants Who Prefer IQOS — 7 Participants
N/A N=150 Methods Project 4: Clinical Trial
Smoker
Primary: Smoke-free Days — 14.5; 0; 0 days
Phase 2 N=391 Efficacy of Oral Tobacco Products Compared to a Medicinal Nicotine
Tobacco Use Disorder
Primary: Product Effect on Complete Substitution for Smoking — 56; 56 participants
N/A N=387 Cigarette Pack Inserts for Smoking Cessation
Smoking Cessation
Primary: Self-efficacy to Quit Smoking — 2.61; 2.76; 2.62; 2.56 score on a scale — p=0.60
N/A N=199 Perceptions of Cigarette Smoking in Young Adults
Smoking, Cigarette
Primary: Subjective Response to Smoking Cigarettes From the Cigarette Evaluation Scale — 4.68; 4.50 score on a scale — p=>.05
Phase 2 N=67 Impact of Smoking Cessation and γ-Tocopherol to Restore Vascular Endothelial Function
Endothelial Dysfunction
Primary: Absolute Change in Brachial Artery Flow-mediated Dilation at Day 7 From Day 0 — 4.08; 2.77; 2.97; 2.66 % of preocclusion diameter
N/A N=184 Brain Nicotine Receptor Density in Veteran Smokers
Positron Emission Tomography
Primary: PET Scan, Rating Scales — 7.1; 8.6; 7.9; 8.0 Vt/fp or mL/cm3